EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial.

摘要: 7003 Background: Erlotinib produces dramatic responses in a subset of patients with NSCLC. Mutations the EGFR tyrosine kinase domain, amplification or polysomy and overexpression on immunohistochemistry have all been associated sensitivity benefit; pts KRAS mutation are commonly resistant to this agent. These correlative studies were prospectively undertaken characterize ability these markers predict response rate, time progression survival BAC treated EGFR-TKI, erlotinib. Methods: One hundred two received erlotinib as part phase II trial (Kris, Proc ASCO 2005); 84 had one more completed. Analysis exons 19 21 (n=82) (Pao, et al PNAS 2004), IHC (n=62) (DAKO) was performed copy number determined by chromogenic situ hybridization (CISH) (n=74) (Zymed); detection ≥ 4 signals per cell considered evidence amplified number. exon 2 (n=79) testing ...